Efficacy and Safety of Aprocitentan in the Treatment of Hypertension: A Meta-Analysis of Evidence from Randomized Controlled Trials
Background: Hypertension is one of the most prevalent disorders encountered in medical practice, yet effective pharmacotherapy options for resistant hypertension are limited. In this meta-analysis, we aimed to evaluate the efficacy and safety of aprocitentan in treating hypertensi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2025-01-01
|
| Series: | Reviews in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/RCM/26/1/10.31083/RCM25909 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586546715295744 |
|---|---|
| author | Li Zheng Ming Liu Xiaotong Gu Yatong Zhang Yan Wang |
| author_facet | Li Zheng Ming Liu Xiaotong Gu Yatong Zhang Yan Wang |
| author_sort | Li Zheng |
| collection | DOAJ |
| description | Background: Hypertension is one of the most prevalent disorders encountered in medical practice, yet effective pharmacotherapy options for resistant hypertension are limited. In this meta-analysis, we aimed to evaluate the efficacy and safety of aprocitentan in treating hypertension. Methods: We searched PubMed, Embase, ClinicalTrials.gov, and the Cochrane Library databases from inception to June 3, 2024, for randomized controlled trials (RCTs) that compared the efficacy and safety between aprocitentan and placebo in treating hypertension. According to the dosage of aprocitentan, the study was divided into a low-dose group (10–12.5 mg), medium-dose group (25 mg), and high-dose group (50 mg). Results: This meta-analysis included five RCTs, which incorporated 1224 patients, and displayed that aprocitentan can reduce the mean sitting systolic blood pressure (msSBP) [(low dose subgroup: mean difference (MD): –3.85 mmHg; 95% confidence interval (CI): –7.47 to –0.23; p = 0.040; medium dose group: MD: –5.56 mmHg; 95% CI: –10.69 to –0.44; p = 0.030)], mean sitting diastolic blood pressure (msDBP) (low dose subgroup: MD: –3.95 mmHg; 95% CI: –4.06 to –3.85; p < 0.001; medium dose group: MD: –4.75 mmHg; 95% CI: –5.91 to –3.60; p < 0.001), 24-hour ambulatory systolic blood pressure (maSBP) (low dose group: MD: –4.18 mmHg; 95% CI: –4.32 to –4.04; p < 0.001; medium dose group: MD: –5.89 mmHg; 95% CI: –6.03 to –5.75; p < 0.001), and 24-hour ambulatory diastolic blood pressure (maDBP) (low dose group: MD: –4.33 mmHg; 95% CI: –4.42 to –4.24; p < 0.001; medium dose group: MD: –5.82 mmHg; 95% CI: –5.91 to –5.73; p < 0.001). In the high-dose group, there was no difference between the aprocitentan and placebo groups in the msSBP (MD: –4.83 mmHg; 95% CI: –11.44 to 1.79; p = 0.150). Meanwhile, the safety profile of aprocitentan was good, and no significant differences in the frequency of adverse events (AEs) and serious adverse events (SAEs) were observed compared to the placebo. Conclusions: Aprocitentan significantly reduces blood pressure and has a good safety profile. However, it is worth noting that high doses of aprocitentan (50 mg) did not yield better blood pressure-lowering effects. |
| format | Article |
| id | doaj-art-f6bb5edd448141a985be6eb7d21713b7 |
| institution | Kabale University |
| issn | 1530-6550 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Reviews in Cardiovascular Medicine |
| spelling | doaj-art-f6bb5edd448141a985be6eb7d21713b72025-01-25T10:41:20ZengIMR PressReviews in Cardiovascular Medicine1530-65502025-01-012612590910.31083/RCM25909S1530-6550(24)01637-5Efficacy and Safety of Aprocitentan in the Treatment of Hypertension: A Meta-Analysis of Evidence from Randomized Controlled TrialsLi Zheng0Ming Liu1Xiaotong Gu2Yatong Zhang3Yan Wang4Department of Pharmacy, China Aerospace Science & Industry Corporation 731 Hospital, 100074 Beijing, ChinaEvidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, 730000 Lanzhou, Gansu, ChinaDepartment of Pharmacy, China Aerospace Science & Industry Corporation 731 Hospital, 100074 Beijing, ChinaDepartment of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, 100730 Beijing, ChinaDepartment of Cardiovascular Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, 100730 Beijing, ChinaBackground: Hypertension is one of the most prevalent disorders encountered in medical practice, yet effective pharmacotherapy options for resistant hypertension are limited. In this meta-analysis, we aimed to evaluate the efficacy and safety of aprocitentan in treating hypertension. Methods: We searched PubMed, Embase, ClinicalTrials.gov, and the Cochrane Library databases from inception to June 3, 2024, for randomized controlled trials (RCTs) that compared the efficacy and safety between aprocitentan and placebo in treating hypertension. According to the dosage of aprocitentan, the study was divided into a low-dose group (10–12.5 mg), medium-dose group (25 mg), and high-dose group (50 mg). Results: This meta-analysis included five RCTs, which incorporated 1224 patients, and displayed that aprocitentan can reduce the mean sitting systolic blood pressure (msSBP) [(low dose subgroup: mean difference (MD): –3.85 mmHg; 95% confidence interval (CI): –7.47 to –0.23; p = 0.040; medium dose group: MD: –5.56 mmHg; 95% CI: –10.69 to –0.44; p = 0.030)], mean sitting diastolic blood pressure (msDBP) (low dose subgroup: MD: –3.95 mmHg; 95% CI: –4.06 to –3.85; p < 0.001; medium dose group: MD: –4.75 mmHg; 95% CI: –5.91 to –3.60; p < 0.001), 24-hour ambulatory systolic blood pressure (maSBP) (low dose group: MD: –4.18 mmHg; 95% CI: –4.32 to –4.04; p < 0.001; medium dose group: MD: –5.89 mmHg; 95% CI: –6.03 to –5.75; p < 0.001), and 24-hour ambulatory diastolic blood pressure (maDBP) (low dose group: MD: –4.33 mmHg; 95% CI: –4.42 to –4.24; p < 0.001; medium dose group: MD: –5.82 mmHg; 95% CI: –5.91 to –5.73; p < 0.001). In the high-dose group, there was no difference between the aprocitentan and placebo groups in the msSBP (MD: –4.83 mmHg; 95% CI: –11.44 to 1.79; p = 0.150). Meanwhile, the safety profile of aprocitentan was good, and no significant differences in the frequency of adverse events (AEs) and serious adverse events (SAEs) were observed compared to the placebo. Conclusions: Aprocitentan significantly reduces blood pressure and has a good safety profile. However, it is worth noting that high doses of aprocitentan (50 mg) did not yield better blood pressure-lowering effects.https://www.imrpress.com/journal/RCM/26/1/10.31083/RCM25909hypertensiondual endothelin receptor antagonistaprocitentanmeta-analysis |
| spellingShingle | Li Zheng Ming Liu Xiaotong Gu Yatong Zhang Yan Wang Efficacy and Safety of Aprocitentan in the Treatment of Hypertension: A Meta-Analysis of Evidence from Randomized Controlled Trials Reviews in Cardiovascular Medicine hypertension dual endothelin receptor antagonist aprocitentan meta-analysis |
| title | Efficacy and Safety of Aprocitentan in the Treatment of Hypertension: A Meta-Analysis of Evidence from Randomized Controlled Trials |
| title_full | Efficacy and Safety of Aprocitentan in the Treatment of Hypertension: A Meta-Analysis of Evidence from Randomized Controlled Trials |
| title_fullStr | Efficacy and Safety of Aprocitentan in the Treatment of Hypertension: A Meta-Analysis of Evidence from Randomized Controlled Trials |
| title_full_unstemmed | Efficacy and Safety of Aprocitentan in the Treatment of Hypertension: A Meta-Analysis of Evidence from Randomized Controlled Trials |
| title_short | Efficacy and Safety of Aprocitentan in the Treatment of Hypertension: A Meta-Analysis of Evidence from Randomized Controlled Trials |
| title_sort | efficacy and safety of aprocitentan in the treatment of hypertension a meta analysis of evidence from randomized controlled trials |
| topic | hypertension dual endothelin receptor antagonist aprocitentan meta-analysis |
| url | https://www.imrpress.com/journal/RCM/26/1/10.31083/RCM25909 |
| work_keys_str_mv | AT lizheng efficacyandsafetyofaprocitentaninthetreatmentofhypertensionametaanalysisofevidencefromrandomizedcontrolledtrials AT mingliu efficacyandsafetyofaprocitentaninthetreatmentofhypertensionametaanalysisofevidencefromrandomizedcontrolledtrials AT xiaotonggu efficacyandsafetyofaprocitentaninthetreatmentofhypertensionametaanalysisofevidencefromrandomizedcontrolledtrials AT yatongzhang efficacyandsafetyofaprocitentaninthetreatmentofhypertensionametaanalysisofevidencefromrandomizedcontrolledtrials AT yanwang efficacyandsafetyofaprocitentaninthetreatmentofhypertensionametaanalysisofevidencefromrandomizedcontrolledtrials |